





an Open Access Journal by MDPI

Opportunities and Challenges in Multiple Myeloma Treatment and Management

Guest Editors:

Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

Dr. Giovanni Martinelli

Department of Hematology and Sciences Oncology, Institute of Haematology "L. and A. Seràgnoli" S. Orsola, University of Bologna, 40126 Bologna, Italy

Deadline for manuscript submissions:

closed (30 May 2023)

Message from the Guest Editors

Dear Colleagues,

Multiple myeloma (MM) is a hematological malignancy characterized by a high propensity for recurrence and drug resistance. A wide range of genetic and epigenetic abnormalities have been implicated in the pathogenesis of this cancer, ultimately affecting the growth, survival and drug sensitivity of multiple myeloma cells.

Although many therapeutic agents have been developed to improve the depth and duration of response and prolong patient survival, the management of multiple myeloma remains challenging due to the eventual emergence of drug-resistant clones and often imminent relapse. These events have prompted continued research to identify new molecular lesions and therapeutic targets, with the ultimate goal of finding a cure for multiple myeloma.

Therefore, this special issue focuses on the tumor microenvironment and mechanisms of deterioration, i.e. drug resistance, proliferative signaling, immune evasion, etc., which are involved in the aggressive disease behavior of refractory MM, to better manage those that develop into new tumors. treatment strategy.

Dr. Claudio Cerchione Dr. Giovanni Martinelli *Guest Editors*



Click here to submit Specialsue







an Open Access Journal by MDPI

Editor-in-Chief

Dr. Claudio Cerchione

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy

Message from the Editor-in-Chief

Hematology Reports (ISSN 2038-8330) is an international open access journal on all aspects of the prevention, diagnosis and management of disorders of the blood, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology and controlled trials. Hematology Reports publishes reviews, regular research papers (articles), case reports and communications. Our aim is to collect high-quality articles that are of interest and cutting-edge in hematology, to provide an efficient, reliable and guaranteed platform for scholars and readers, and to encourage scientists to publish their experimental and theoretical research in as much detail as possible. Full experimental and/or methodological details must be provided for research articles.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, and other databases.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 39.1 days after submission; acceptance to publication is undertaken in 3.7 days (median values for papers published in this journal in the second half of 2024).

Contact Us